Skip to main content

Advertisement

Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry

Fig. 3

Last documented response for the tociizumab (TOC) cohort (a), combined IL-1 inhibitor (IL-1i) cohort (b), canakinumab cohort (c) and anakinra (ANA) cohort (d). The rate of patients with no active joints, no fever, Juvenile Disease Activity Score (JADAS)-remission, American College of Rheumatology (ACR)-defined inactive disease, ACR-remission is given, respectively, in the total cohort and for biologic-naive and pre-exposed patients. Differences in rates were calculated using the chi-square-test. Pearson’s p value is outlined if < 0.05. ETA, etanercept

Back to article page